http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108977409-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-125 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2302 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2315 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2307 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2304 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-998 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-71 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 |
| filingDate | 2018-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108977409-B |
| titleOfInvention | Culture medium for human-derived lymphocytes, preparation method and application thereof |
| abstract | The invention discloses a human-derived lymphocyte culture medium which comprises an RPMI1640 culture medium, human serum albumin, human catalase, methionine enkephalin, stem cell growth factors, human transferrin, palmitic acid, folic acid, interleukin 4, interleukin 2, hypoxanthine, gentamicin, IL-7, IL-15 and the like. The invention also discloses a method for preparing the culture medium and a method for culturing T lymphocytes by using the culture medium. The culture medium provided by the invention can realize the culture and efficient amplification of the human T lymphocyte, has the enhanced capacity of specifically killing the antigen-targeted tumor cells, and also has the advantages of long quality guarantee period, easiness in preparation and the like. |
| priorityDate | 2018-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 290.